MGMT and glioblastoma: A phase 1 clinical trial examined the immune checkpoint inhibition with nivolumab for newly diagnosed O6-methylguanine–DNA methyltransferase (MGMT)-methylated GBM (NCT02667587), but it was canceled later due to poor outcomes.